GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (OTCPK:LSDIF) » Definitions » Debt-to-EBITDA

LSDIF (Lucy Scientific Discovery) Debt-to-EBITDA : -0.47 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lucy Scientific Discovery's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.49 Mil. Lucy Scientific Discovery's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.72 Mil. Lucy Scientific Discovery's annualized EBITDA for the quarter that ended in Dec. 2023 was $-4.70 Mil. Lucy Scientific Discovery's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.47.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lucy Scientific Discovery's Debt-to-EBITDA or its related term are showing as below:

LSDIF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.27   Med: -0.93   Max: -0.26
Current: -0.26

During the past 3 years, the highest Debt-to-EBITDA Ratio of Lucy Scientific Discovery was -0.26. The lowest was -1.27. And the median was -0.93.

LSDIF's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs LSDIF: -0.26

Lucy Scientific Discovery Debt-to-EBITDA Historical Data

The historical data trend for Lucy Scientific Discovery's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery Debt-to-EBITDA Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
Debt-to-EBITDA
-0.93 -1.27 -0.26

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -8.70 -0.13 -0.21 -0.28 -0.47

Competitive Comparison of Lucy Scientific Discovery's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucy Scientific Discovery's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's Debt-to-EBITDA falls into.



Lucy Scientific Discovery Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lucy Scientific Discovery's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.399 + 1.39) / -6.921
=-0.26

Lucy Scientific Discovery's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.494 + 0.719) / -4.7
=-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Lucy Scientific Discovery  (OTCPK:LSDIF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lucy Scientific Discovery Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucy Scientific Discovery Business Description

Traded in Other Exchanges
N/A
Address
301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.
Executives
Richard D Nanula director, officer: Executive Chairman C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko officer: Chief Financial Officer C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany director, officer: President and CEO C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy officer: Chief Scientific Officer C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6

Lucy Scientific Discovery Headlines